Traduction de «active ingredient in afinitor » (Néerlandais → Français) :

Everolimus, the active ingredient in Afinitor, is also available under the trade names Zortress/Certican for use in nononcology indications.
Evérolimus, la substance active d’Afinitor, est également disponible sous les marques Certican/Zortress pour son utilisation dans des indications non oncologiques.

This medicine, which has the same active ingredient as Afinitor (everolimus), has been shown to have good immunosuppressive efficacy and a manageable side-effect profile.
Ce médicament qui contient de l’évérolimus, la même substance active qu’Afinitor, a démontré une bonne efficacité immunosuppressive et un profil d’effets secondaires gérables.

Everolimus, the active ingredient in Afinitor, is also available under the trade names Certican/Zortress for use in non-oncology indications.
Evérolimus, la substance active d’Afinitor, est également disponible sous les marques Certican/Zortress pour son utilisation dans des indications non oncologiques.

Everolimus, the active ingredient in Certican/Zortress, is also available under the trade name Afinitor for use in an oncology indication.
Evérolimus, la substance active Certican/Zortress, est également disponible sous la marque Afinitor pour son utilisation dans une indication oncologique.

2010 selected major approvals: US, Europe and Japan Product Active ingredient Indication Approval date Afinitor Everolimus Kidney cancer Japan – Q1 Equa (Galvus) Vildagliptin Type 2 diabetes Japan – Q1 Exforge Valsartan and amlodipine Hypertension Japan – Q1
Autorisations importantes en 2010 Aux Etats-Unis, en Europe et au Japon Produit Substance active Indication Date d’autorisation Afinitor Evérolimus Cancer du rein Japon – T1 Equa (Galvus) Vildagliptine Diabète de type 2 Japon – T1 Exforge valsartan et amlodipine Hypertension Japon – T1

Everolimus is also the active ingredient in the anti-cancer therapy Afinitor, which has been approved in the US.
Evérolimus est aussi la substance active d'Afinitor, un traitement anticancer homologué aux Etats-Unis.

●● Efficacy: the active ingredient is as such subject to an authorisation or prequalification by the WHO or a positive opinion from the EMEA During this first year of activity, The Production & Distribution department issued 149 EDs.
●● Efficacy: the active ingredient is as such subject to an authorisation or prequalification by the WHO or a positive opinion from the EMEA During this first year of activity, The Production & Distribution department issued 149 EDs.

Active pharmacovigilance In the context of the FAMHP’s decision to promote proactive pharmacovigilance, a decision was made at the end of 2007 to encourage healthcare professionals to pay extra attention to adverse effects that arise after taking medicines with a new active ingredient (the “black triangle” project - during
Active pharmacovigilance In the context of the FAMHP’s decision to promote proactive pharmacovigilance, a decision was made at the end of 2007 to encourage healthcare professionals to pay extra attention to adverse effects that arise after taking medicines with a new active ingredient (the “black triangle” project - during

medicines for human use and veterinary medicines, raw materials (active ingredients) for pharmacists, establishment of retail pharmacies, medical devices) ●● Management of possible crisis situations ●● Coordination of the (inter)national representation of the FAMHP ●● The difference between the roles of “Communication” versus “Information” ●● Points of entry for applications submitted to
medicines for human use and veterinary medicines, raw materials (active ingredients) for pharmacists, establishment of retail pharmacies, medical devices) ●● Management of possible crisis situations ●● Coordination of the (inter)national representation of the FAMHP ●● The difference between the roles of “Communication” versus “Information” ●● Points of entry for applications submitted to

We adopt a risk-based approach and focus on minimizing our use of natural resources, cutting our energy consumption and emissions, and preventing active ingredients from entering the environment.
Notre approche est basée sur une évaluation des risques ; nous nous efforçons de réduire au minimum notre exploitation des ressources naturelles, d’abaisser notre consommation d’énergie et nos émissions de gaz polluants dans l’air, et nous prenons toutes les mesures adéquates pour empêcher les émanations de substances actives en dehors de nos laboratoires.